Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Investor Call held on August 10, 2022 for Q1 FY2022-23 results13-08-2022
13-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company is going to participate in Emkay Investor Conference 2022 virtually on August 12, 202212-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter ended on June 30, 2022 in Financial Express on August 11, 2022.11-08-2022
Zydus Lifesciences Ltd - 532321 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Zydus Lifesciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here11-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Prochlorperazine Maleate Tablets11-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the Investor call on financial results for quarter ended June 30, 202210-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Re-appointment of Statutory Auditors for the second and final term of five consecutive years10-08-2022
Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Disclosure under regulation 44(3)10-08-2022
Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 27th Annual General Meeting10-08-2022
Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizers report - Consolidated10-08-2022